Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sunshine Biopharma (SBFM) Common Equity (2016 - 2025)

Sunshine Biopharma's Common Equity history spans 14 years, with the latest figure at $23.0 million for Q4 2025.

  • For Q4 2025, Common Equity fell 1.97% year-over-year to $23.0 million; the TTM value through Dec 2025 reached $23.0 million, down 1.97%, while the annual FY2025 figure was $23.0 million, 1.97% down from the prior year.
  • Common Equity reached $23.0 million in Q4 2025 per SBFM's latest filing, down from $24.2 million in the prior quarter.
  • In the past five years, Common Equity ranged from a high of $41.9 million in Q2 2022 to a low of -$1.2 million in Q3 2021.
  • Average Common Equity over 5 years is $19.6 million, with a median of $22.9 million recorded in 2025.
  • Peak YoY movement for Common Equity: tumbled 111.57% in 2021, then skyrocketed 10117.97% in 2022.
  • A 5-year view of Common Equity shows it stood at $211662.0 in 2021, then surged by 10117.97% to $21.6 million in 2022, then fell by 1.94% to $21.2 million in 2023, then grew by 10.81% to $23.5 million in 2024, then fell by 1.97% to $23.0 million in 2025.
  • Per Business Quant, the three most recent readings for SBFM's Common Equity are $23.0 million (Q4 2025), $24.2 million (Q3 2025), and $25.7 million (Q2 2025).